Alfresa Holdings Corporation (ALFRY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 10.62 means the share price is 10.62 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $2.46B is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAlfresa Holdings Corporation (ALFRY) trades at $13.55. Alfresa Holdings Corporation operates in the healthcare sector, focusing on pharmaceutical distribution, manufacturing, and medical-related services. Market cap: $2.46B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ALFRY: ALFRY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALFRY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
ALFRY: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Alfresa Holdings Corporation (ALFRY) Healthcare & Pipeline Overview
Alfresa Holdings Corporation, a Japanese healthcare conglomerate, manufactures, wholesales, and distributes pharmaceuticals, diagnostic reagents, and medical devices. With a focus on ethical pharmaceuticals and self-medication products, the company serves hospitals, clinics, and pharmacies in Japan and internationally, maintaining a stable position in the medical distribution landscape.
What Is the Investment Thesis for ALFRY?
Alfresa Holdings Corporation presents a stable investment profile within the healthcare distribution sector. The company's diversified revenue streams, spanning ethical pharmaceuticals, self-medication products, and manufacturing, provide resilience against market fluctuations. With a P/E ratio of 10.62 and a dividend yield of 2.76% as of 2026-03-16, Alfresa offers a blend of value and income potential. The company's low beta of -0.16 suggests a lower sensitivity to market volatility compared to its peers. Growth catalysts include expanding its self-medication product lines and penetrating new international markets. Potential risks include regulatory changes in the pharmaceutical industry and increased competition from other distributors.
Based on FMP financials and quantitative analysis
ALFRY Key Highlights
Market capitalization of $2.46B indicates a substantial presence in the healthcare sector.
- P/E ratio of 10.62 suggests a reasonable valuation compared to earnings.
- Dividend yield of 2.76% provides a steady income stream for investors.
- Gross margin of 7.1% reflects the company's ability to manage its cost of goods sold.
- Profit margin of 1.1% indicates areas for potential improvement in operational efficiency.
Who Are ALFRY's Competitors?
ALFRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CHSYF China Medical System Holdings Limited | $1.57 | 0.00% | $3.80B | — |
| DMPHF Dermapharm Holding SE | $47.69 | 0.00% | $2.36B | — |
| HAWPF Haw Par Corporation Limited | $10.80 | -14.12% | $2.39B | — |
| HTSUF Hisamitsu Pharmaceutical Co., Inc. | $29.00 | 0.00% | $2.04B | — |
| MAHLY MediPal Holdings Corporation | $18.30 | 0.00% | $3.75B | — |
| PBH Prestige Consumer Healthcare Inc. | $47.34 | -2.79% | $2.24B | 625-pillar |
| GRDN Guardian Pharmacy Services, Inc. | $43.66 | -0.39% | $2.76B | 965-pillar |
| PDCO Patterson Companies, Inc. | $31.33 | -0.90% | $2.77B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALFRY's Key Strengths?
Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.
- Established distribution network in Japan.
- Strong relationships with key customers, including hospitals and pharmacies.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
What Are ALFRY's Weaknesses?
Relatively low profit margin compared to industry peers.
- Dependence on the Japanese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited international presence compared to global competitors.
What Could Drive ALFRY Stock Higher?
ALFRY catalyst: Expansion of self-medication product lines to meet growing consumer demand for OTC drugs and health supplements.
- Strategic partnerships to enhance distribution network and market reach in key regions.
- Potential regulatory approvals for new pharmaceutical products, expanding the company's product portfolio.
- Investment in digital distribution channels to capitalize on the growth of e-pharmacy market.
- Development of value-added services to enhance customer loyalty and generate recurring revenue.
What Are the Key Risks for ALFRY?
Increased competition from other pharmaceutical distributors, leading to pricing pressures.
- Changes in government regulations and healthcare policies, affecting reimbursement rates and market access.
- Economic downturns affecting healthcare spending and consumer demand for pharmaceuticals.
- Currency fluctuations between the U.S. dollar and the Japanese yen, impacting the value of the ADR.
- Product liability claims or recalls, damaging the company's reputation and financial performance.
What Are the Growth Opportunities for ALFRY?
- Expanding Self-Medication Product Lines: Alfresa can capitalize on the growing demand for over-the-counter drugs and health supplements. The global self-medication market is projected to reach $200 billion by 2028. By introducing innovative products and expanding its distribution network, Alfresa can increase its market share in this segment. Timeline: Ongoing.
- Penetrating New International Markets: Alfresa has the opportunity to expand its presence in emerging markets with growing healthcare needs. The Asia-Pacific region, in particular, offers significant growth potential. By establishing partnerships and adapting its product offerings to local market demands, Alfresa can diversify its revenue streams. Timeline: 2-3 years.
- Enhancing Contract Manufacturing Services: Alfresa can leverage its manufacturing capabilities to offer contract manufacturing services to other pharmaceutical companies. The global pharmaceutical contract manufacturing market is expected to reach $150 billion by 2027. By investing in advanced manufacturing technologies and expanding its capacity, Alfresa can attract new clients and generate additional revenue. Timeline: Ongoing.
- Strengthening Digital Distribution Channels: Alfresa can enhance its online presence and develop digital distribution channels to reach a wider customer base. The e-pharmacy market is experiencing rapid growth, driven by increasing internet penetration and changing consumer preferences. By investing in e-commerce platforms and digital marketing strategies, Alfresa can capture a share of this growing market. Timeline: 1-2 years.
- Developing Value-Added Services: Alfresa can differentiate itself from competitors by offering value-added services to its customers, such as inventory management, supply chain optimization, and data analytics. These services can help hospitals, clinics, and pharmacies improve their operational efficiency and reduce costs. By providing customized solutions and building strong customer relationships, Alfresa can enhance customer loyalty and generate recurring revenue. Timeline: Ongoing.
What Are ALFRY's Competitive Advantages?
- Established distribution network in Japan.
- Diversified product portfolio spanning pharmaceuticals, diagnostics, and medical devices.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
- Strong relationships with hospitals, clinics, and pharmacies.
What Does ALFRY Do?
Incorporated in 2003 and based in Tokyo, Japan, Alfresa Holdings Corporation has established itself as a key player in the healthcare sector. The company operates through its subsidiaries, engaging in the manufacture, wholesale, marketing, and import/export of a diverse range of healthcare products. These include pharmaceuticals, diagnostic reagents, and medical devices/equipment. Alfresa's operations are segmented into ethical pharmaceuticals wholesaling, self-medication products wholesaling, and manufacturing. The ethical pharmaceuticals division supplies hospitals, clinics, and dispensing pharmacies with essential products. The self-medication division caters to drug stores and pharmacies, offering over-the-counter drugs, health foods, and supplements. Alfresa also manufactures active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, providing contract manufacturing services. The company's medical-related business encompasses dispensing pharmacies and other healthcare activities, further solidifying its presence in the healthcare value chain. Alfresa's international reach extends its market presence beyond Japan, contributing to its revenue streams and overall growth.
What Products and Services Does ALFRY Offer?
- Wholesales ethical pharmaceuticals to hospitals, clinics, and dispensing pharmacies.
- Distributes self-medication products, including OTC drugs and health supplements, to drug stores and pharmacies.
- Manufactures active pharmaceutical ingredients and pharmaceuticals.
- Produces diagnostic reagents and medical devices.
- Offers contract manufacturing services for pharmaceuticals.
- Operates dispensing pharmacies.
How Does ALFRY Make Money?
- Revenue from wholesale distribution of pharmaceuticals and medical products.
- Income from manufacturing and sales of active pharmaceutical ingredients and finished drugs.
- Fees from contract manufacturing services.
- Revenue generated from operation of dispensing pharmacies.
What Industry Does ALFRY Operate In?
Alfresa Holdings Corporation operates within the medical distribution industry, a sector characterized by steady growth driven by aging populations and increasing healthcare expenditure. The industry is competitive, with players like CHSYF, DMPHF, HAWPF, HTSUF, and MAHLY vying for market share. Trends include consolidation among distributors and increased focus on supply chain efficiency. Alfresa's diversified product portfolio and established distribution network position it favorably within this landscape.
Who Are ALFRY's Key Customers?
- Hospitals and clinics.
- Dispensing pharmacies.
- Drug stores.
- Other pharmaceutical companies (for contract manufacturing).
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in JPY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 49 |
| 2026-08-26 | 49 |
| 2026-08-29 | 49 |
| 2026-09-01 | 49 |
| 2026-09-04 | 49 |
| 2026-09-07 | 49 |
| 2026-09-10 | 49 |
What changed?
The score has stayed at 49.
Over the same 18 days the stock moved +0.0%.
Financial Health
Alfresa Holdings Corporation's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.98 places it in the grey zone, a middle ground that warrants monitoring.
Key Financial Metrics
Return on equity for Alfresa Holdings Corporation stands at 8.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.8%, showing how much profit it generates from its asset base. ALFRY trades at a trailing price-to-earnings ratio of 10.62, below the Healthcare sector average of ~21.50x. A current ratio of 1.24 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.6%, the inverse of the P/E and a quick read on earnings relative to price.
Alfresa Holdings Corporation (ALFRY) Valuation Context
Valued at $2.46B, ALFRY is classified as a mid-cap stock.
ALFRY Revenue & Earnings Trend
In Q1 FY2027, ALFRY generated $5.20B in top-line revenue, marking a sequential increase of 5.9%. The company recorded net income of $16.3M, with diluted EPS of $0.09. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, ALFRY averaged $0.36 in diluted EPS.
Company Profile
Alfresa Holdings Corporation operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Ryuji Arakawa. ALFRY has traded publicly since 2018.
ALFRY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.
- Established distribution network in Japan.
- Strong relationships with key customers, including hospitals and pharmacies.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
Bear Case
- Relatively low profit margin compared to industry peers.
- Dependence on the Japanese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited international presence compared to global competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2027 | $5.20B | $16M | $0.09 |
| Q4 FY2026 | $4.91B | $65M | $0.35 |
| Q3 FY2026 | $5.52B | $136M | $0.75 |
| Q2 FY2026 | $5.11B | $43M | $0.23 |
Q1 FY2027 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from JPY at today's rate
ALFRY Latest News
No recent news available for ALFRY.
ALFRY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ALFRY.
Price Targets
Wall Street price target analysis for ALFRY.
ALFRY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ALFRY; grades run from A+ (80-100) to F (below 30).
Leadership: Ryuji Arakawa
Unknown
However, as the managing leader of Alfresa Holdings Corporation's 12,517 employees, Arakawa likely possesses extensive experience in the pharmaceutical or healthcare distribution industry. Further research would be needed to ascertain specific details about his education, previous roles, and credentials.
Track Record: Due to the limited information available, Ryuji Arakawa's specific achievements and strategic decisions as CEO of Alfresa Holdings Corporation cannot be detailed. Evaluating his track record would require access to company performance data, strategic initiatives, and key milestones achieved under his leadership.
Alfresa Holdings Corporation ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. ALFRY is an ADR representing shares of Alfresa Holdings Corporation, allowing U.S. investors to invest in the Japanese company without directly dealing with foreign exchanges. The ADR is denominated in U.S. dollars, simplifying trading and investment for U.S. investors.
- Home Market Ticker: Tokyo Stock Exchange, Japan
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: ALFR
ALFRY OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to be SEC reporting.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in ALFRY.
- Low trading volume and wide bid-ask spreads can lead to price volatility and illiquidity.
- Lack of regulatory oversight increases the risk of fraud or manipulation.
- Potential for delisting or suspension of trading.
- Difficulty obtaining accurate and timely information about the company.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a qualified financial advisor.
- Understand the OTC market and its associated risks.
- The company is an established player in the healthcare sector.
- Alfresa Holdings Corporation is based in Japan, a country with strong corporate governance standards.
- The company has a long operating history.
- ALFRY is an ADR, suggesting some level of scrutiny and compliance.
- The company has a market capitalization of $2.46B, indicating a substantial business.
ALFRY Healthcare Stock FAQ
Is ALFRY a good stock?
Stock Expert AI does not rate ALFRY buy, sell or hold. Alfresa Holdings Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for ALFRY?
Alfresa Holdings Corporation faces several risks inherent to the healthcare distribution industry. These include increased competition from other pharmaceutical distributors, pricing pressures from generic drugs, and changes in government regulations and healthcare policies. Additionally, the company is exposed to currency fluctuations between the U.S. dollar and the Japanese yen, as well as potential product liability claims or recalls.
What are the key factors to evaluate for ALFRY?
Evaluate ALFRY on fundamentals, analyst consensus, and risk factors. P/E: 10.62x vs the S&P 500's ~20-25x. With a P/E ratio of 10.62 and a dividend yield of 2.76% as of 2026-03-16, Alfresa offers a blend of value and income potential. Not financial advice.
How frequently does ALFRY data refresh on this page?
ALFRY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ALFRY's recent stock price performance?
Alfresa Holdings Corporation (ALFRY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified revenue streams across wholesale, manufacturing, and pharmacy operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ALFRY overvalued or undervalued right now?
Alfresa Holdings Corporation (ALFRY) trades at 10.62x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ALFRY?
Yes, most major brokerages offer fractional shares of Alfresa Holdings Corporation (ALFRY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ALFRY's earnings and financial reports?
Alfresa Holdings Corporation (ALFRY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ALFRY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- Analyst consensus and detailed CEO background information are limited.
- OTC market data may be less reliable than exchange-listed data.